NASDAQ$LGVN
Longeveron Inc-A · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results and corporate update for the fourth quarter and full year of 2022.
Longeveron reported fourth quarter revenue of $0.1 million and a net loss of $4.5 million. The company's cash and short-term investments totaled $19.6 million. They believe that existing cash and short-term investments will be sufficient to cover expenses and capital requirements into the first half of 2024.
- Longeveron executed on multiple key milestones, advancing Lomecel-BTM for multiple indications in 2022.
- Full data from the ELPIS I trial of Lomecel-BTM for infants with HLHS was published in European Heart Journal Open.
- Progress was made with the Japan Aging-Related Phase 2 study.
- First patient to be randomized in Japan Aging-Related Phase 2 study in Q1.
Headline financials
Revenue & EPS history
Longeveron · Revenue · Quarterly
$121K
Revenue by segment
Longeveron · $150K total across 1 segment · Q4 2023
- Clinical Trial Revenue$150K—100.0%
Forward guidance
Based on the Company’s current operating plan and financial resources, they believe that their existing cash and short-term investments will be sufficient to cover expenses and capital requirements into first half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-5.1%
Avg return
Earnings day
-5.7%
Avg return
5 days after
+23.1%
Avg return
30 days after
35%
7 / 20 earnings
Positive
+10.0%
Q1 2022
Best reaction
-35.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -11.0% | — | |
| Q4 2025 | -4.7% | -0.7% | +6.1% | |
| Q3 2025 | -4.3% | -7.3% | -23.1% | |
| Q1 2025 | -10.1% | -9.4% | -17.4% | |
| Q4 2024 | -9.2% | -5.3% | +2.0% | |
| Q3 2024 | -2.3% | -8.8% | -14.3% | |
| Q2 2024 | -7.5% | -11.3% | -21.8% | |
| Q1 2024 | +3.1% | -1.5% | +106.9% | |
| Q4 2023 | +0.7% | +0.0% | -39.8% | |
| Q3 2023 | -6.7% | -0.5% | +17.6% | |
| Q2 2023 | -6.5% | -12.0% | -25.8% | |
| Q1 2023 | -6.1% | -11.9% | -0.9% | |
| Q4 2022 | -15.5% | -17.5% | -25.0% | |
| Q3 2022 | +5.1% | +2.6% | -14.1% | |
| Q2 2022 | +3.9% | +1.3% | -14.5% | |
| Q1 2022 | +10.0% | +16.2% | -0.7% | |
| Q4 2021 | -14.4% | -7.1% | +37.8% | |
| Q3 2021 | -4.9% | -15.6% | +461.6% | |
| Q2 2021 | -35.7% | -32.9% | -31.1% | |
| Q1 2021 | +1.7% | +17.9% | +35.8% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro